Pegylated Liposomal Doxorubicin (Caelyx®) in Metastatic Breast Cancer: A Community-Based Observation Study
Authors:
- Beat ThürlimannBTBeat Thürlimann
- Ursula HaslerUHUrsula Hasler
- Geoffrey DelmoreGDGeoffrey Delmore
- Albert von RohrARAlbert von Rohr
- Annatina ThürlimannATAnnatina Thürlimann
- Thomas RuhstallerTRThomas Ruhstaller
- Shanna StopatschinskajaSSShanna Stopatschinskaja
- Roger von MoosRMRoger von Moos
- 17 December 2007
- journal article
- Published by S. Karger AG in Oncology
- Vol. 72 (3-4) , 147-151
Abstract
Objectives: Pegylated liposomal doxorubicin (PLD) has improved therapy options significantly, as it causes less myelosuppression, nausea, vomiting, and alopecia than conventional doxorubicin, while maintaining efficacy. The goal of this survey was to determine whether the use of PLD in a community-based patient group is comparable regarding chemotherapeutic doses and side effects to preselected study patients. Methods: 100 questionnaires were randomly sent to Swiss oncologists in private practices, general hospitals and university hospitals. Results: The patient cohort was heterogeneous with respect to prior treatments. PLD was an active agent in metastatic breast cancer and was well tolerated by the majority of patients. The most common non-hematological side effects were hand-foot syndrome (HFS) and mucositis while only patients receiving a dose of 50 mg/m2 (recommended dose) experienced grade 4 HFS. The reported mean dose of PLD was 38.5 mg/m2. Conclusions: This community-based observational study supports previous reports indicating that PLD at a median dose of ≤40 mg/m2 every 4 weeks is an active, well-tolerated agent in non-selected, pretreated patients with metastatic breast cancer.Keywords
This publication has 20 references indexed in Scilit:
- Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II TrialJournal of Clinical Oncology, 2006
- Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m2 Every 4 Weeks in Previously Treated Patients with Metastatic Breast CancerOncology, 2006
- Randomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast CancerJournal of Clinical Oncology, 2004
- Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancerAnnals of Oncology, 2004
- Liposomal Anthracyclines in Metastatic Breast Cancer: Clinical UpdateThe Oncologist, 2003
- Liposomal Doxorubicin in Ovarian, Peritoneal, and Tubal Carcinoma: A Retrospective Comparative Study of Single-Agent DosagesGynecologic Oncology, 2001
- Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinomaCancer, 2000
- Phase 2 Trial of Liposomal Doxorubicin (40 mg/m2) in Platinum/Paclitaxel-Refractory Ovarian and Fallopian Tube Cancers and Primary Carcinoma of the PeritoneumGynecologic Oncology, 2000
- Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomesCancer, 1999
- Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogsHuman & Experimental Toxicology, 1999